Ulcerative colitis is a chronic inflammatory bowel disease in which the immune system attacks the lining of the colon, causing inflammation, ulceration, abdominal pain, diarrhea and, in some cases, rectal bleeding. Its development is influenced by genetic susceptibility, immune dysfunction and environmental factors, and the condition is becoming an increasing public-health concern worldwide. Although existing therapies can suppress inflammation and induce remission, many patients require long-term treatment, and some eventually lose responsiveness or experience significant side effects. Researchers have therefore been searching for compounds that can influence inflammation while also repairing the chemical damage that accompanies it. Oxidative stress is especially important in this process. When reactive oxygen species accumulate faster than cells can remove them, they damage proteins, lipids and DNA, weaken the intestinal barrier and amplify immune signaling. This creates a damaging feedback loop in which inflammation generates oxidative stress, and oxidative stress intensifies inflammation.

The new work focused on Caulerpa peltata, a green macroalga belonging to a genus known for producing chemically diverse natural products. The researchers prepared an ethanolic extract, referred to as CPEE, and first examined its phytochemical composition and antioxidant capacity. Their screening indicated that the extract contained high levels of flavonoids and tannins, two broad classes of plant and algal compounds often associated with the ability to neutralize reactive molecules or influence cellular signaling. Such screening does not identify a single active drug, however. An extract is a complex mixture, and its biological effects may arise from several compounds acting together, from one dominant molecule, or from chemical interactions that change how individual constituents are absorbed and metabolized. The team therefore combined chemical analysis with biological testing and computer-based modeling to build a more complete picture of how CPEE might work.

Before testing the extract in a disease model, the researchers investigated its safety at concentrations ranging from 1.25 to 100 micrograms per milliliter using zebrafish embryotoxicity assays. Zebrafish embryos are widely used in early toxicology because their development is rapid, their transparent bodies make morphological changes easy to observe, and many basic cellular pathways are conserved with other vertebrates. In this study, the reported screening identified concentrations considered safe for subsequent investigation. That result is an initial safety signal rather than proof of safety in humans: an exposure that does not disrupt zebrafish development may still behave differently in mammals, and an extract administered to the body can produce metabolites not present in a laboratory dish. Nevertheless, the zebrafish stage allowed the researchers to narrow the experimental range before moving to mice and to examine whether the seaweed preparation caused obvious developmental or biochemical abnormalities.

The main animal experiment used BALB/c mice in which acute colitis was induced with dextran sodium sulfate, commonly abbreviated DSS. DSS damages the protective epithelial lining of the colon, allowing bacteria and inflammatory molecules to come into closer contact with tissue and provoking a reproducible inflammatory response. This model is not a replica of every feature of human ulcerative colitis, but it is widely used to study intestinal barrier failure, immune activation and oxidative injury. After colitis was induced, mice received CPEE at 100 milligrams per kilogram for seven days. Compared with untreated mice exposed to DSS, the treated animals showed reduced disease severity and less pathological damage, according to the study. The extract also helped maintain antioxidant enzyme activity, suggesting that its effects were not limited to suppressing visible inflammation but extended to the biochemical defenses that normally keep reactive oxygen species under control.

The molecular centerpiece of the findings was the Nrf2 pathway. Under resting conditions, the transcription factor Nrf2 is held in check by the protein Keap1, which helps direct Nrf2 toward degradation. When cells encounter oxidative or electrophilic stress, chemical changes in Keap1 can release Nrf2. The freed transcription factor moves into the nucleus, binds antioxidant response elements in DNA and increases production of protective proteins. Among the genes and enzymes associated with this response are heme oxygenase 1, or HO-1, and NAD(P)H quinone dehydrogenase 1, known as NQO1. HO-1 helps process heme and can generate products with cytoprotective effects, while NQO1 supports the reduction of reactive quinones and limits redox cycling. In the mouse colon, CPEE treatment improved expression of Nrf2, HO-1 and NQO1, linking the extract’s antioxidant effects to a defined cellular defense program rather than to nonspecific chemical scavenging alone.

The researchers also used liquid chromatography–mass spectrometry to characterize bioactive compounds in the extract and then applied molecular docking and molecular-dynamics simulations to predict how those compounds might interact with Keap1. Molecular docking estimates how a small molecule could fit into a protein’s binding pocket and calculates a predicted binding energy. Molecular dynamics goes further by simulating the movement of atoms over time, allowing researchers to ask whether a proposed interaction remains stable under changing molecular conditions. The computational analysis supported stable interactions between compounds identified in CPEE and Keap1. These results are mechanistically suggestive, but they do not demonstrate that the same compounds reach the relevant tissues at sufficient concentrations inside a living animal. Docking scores are hypotheses about binding, not measurements of drug action. Confirming the mechanism will require purification of individual molecules, biochemical binding assays, genetic tests of the Nrf2–Keap1 system and pharmacokinetic studies showing how the compounds are absorbed and distributed.

The study’s appeal lies in the way it connects marine biodiversity with a therapeutic problem that remains difficult to solve. Seaweeds of the Caulerpa genus have been investigated for antioxidant, anti-inflammatory and other biological activities, and related compounds such as caulerpin have shown protective effects in experimental models of colitis. The new results add C. peltata extract to that growing research landscape, while pointing specifically to Nrf2-related signaling as a potential explanation for its protective activity. Yet the distance between a promising mouse experiment and a clinically useful treatment is substantial. The researchers tested an acute DSS model over seven days, not the prolonged, relapsing disease experienced by many patients. The extract’s precise active ingredients, optimal dose, long-term toxicity, effects on the gut microbiome and interactions with standard medicines remain unresolved. The datasets generated in the work are available from the corresponding author upon reasonable request, creating an opportunity for independent analysis and follow-up studies.

For now, the findings suggest that Caulerpa peltata is best viewed not as an unproven dietary cure, but as a chemically rich source for drug discovery. If future experiments confirm that its compounds selectively activate protective antioxidant signaling without suppressing necessary immune functions, they could help inspire new treatments designed to protect the intestinal barrier while reducing inflammation. Such therapies might eventually take the form of purified molecules, standardized extracts or targeted delivery systems that release active compounds in the colon. Before any of those possibilities can be considered for patients, researchers will need to reproduce the results, identify the molecules responsible, establish rigorous manufacturing standards and test safety and efficacy in progressively more realistic models, followed by carefully controlled clinical trials. The seaweed’s promise is therefore real but preliminary: its most important contribution may be showing how an organism growing in the ocean can illuminate a molecular route toward treating disease in the gut.

Living clinical guidelines represent an evolution beyond traditional static protocols by continuously integrating emerging therapeutic insights and clinical practice changes in real time. Unlike conventional guidelines that remain fixed until periodic updates, living guidelines provide a flexible, iterative framework enabling gastroenterologists to adapt their care approaches rapidly as new evidence becomes available. This adaptable methodology is particularly critical in IBD, where therapeutic landscapes are shifting rapidly due to novel biologics, small molecules, and personalized treatment strategies.

Latica’s proprietary data platform lies at the core of this study’s innovative approach. It enables the secure aggregation and de-identification of vast quantities of electronic health record (EHR) data from community gastroenterology practices, starting with Gastro Health and Allied Digestive Health, which collectively represent some of the most extensive GI practice networks within the United States. Latica’s platform excels in transforming heterogeneous and often unstructured medical documentation — including physician notes, lab results, and imaging reports — into structured, analyzable data, leveraging state-of-the-art natural language processing (NLP) and machine learning algorithms.

By tapping into this real-world evidence, the study aims to elucidate the true clinical and operational impacts of AGA’s ulcerative colitis living guideline as it is adopted in everyday outpatient settings. Key endpoints include measuring actual treatment adoption rates, the evolution of patient care pathways, and resulting clinical outcomes such as remission rates, hospitalization frequencies, and therapy adherence. This granular insight into real-world practice variations and outcomes is indispensable for closing the translational gap between guideline recommendations and tangible improvements in patient health.

AGA President Dr. Lawrence Kim underscores the necessity of this initiative, emphasizing that rapidly evolving treatment modalities necessitate robust mechanisms to monitor how guidelines perform in actual clinical environments. The real-world data generated will not only reinforce evidence-based recommendations but also inform payor strategies and healthcare policy, ultimately fostering alignment across the healthcare ecosystem to optimize resource utilization and patient care quality.

Latica CEO and co-founder Omer Dror further highlights the transformative potential borne from combining AI with expansive clinical datasets. With the power to mine granular clinical narratives and detect nuanced treatment patterns at scale, this collaboration seeks to generate evidence with unprecedented depth and precision. The study’s analytical capabilities extend beyond descriptive statistics, employing predictive modeling to anticipate patient trajectories and identify care bottlenecks, enabling proactive clinical interventions.

From a community practice standpoint, leaders like Dr. Eugenio Hernandez of Gastro Health express optimism about leveraging these innovations to measure guideline adherence and identify gaps in care. The capacity to continuously assess guideline efficacy in varied real-world patient populations allows clinicians to recalibrate and personalize therapeutic regimens, thus advancing the frontier of precision gastroenterology.

Likewise, Dr. Nadeem Baig, Chief Medical Officer of Allied Digestive Health, notes that integrating Latica’s AI-driven insights aligns seamlessly with their organization’s mission of delivering high-quality, compassionate GI care. By rigorously evaluating guideline implementation in diverse community settings, this collaborative study promises to not only elevate standardization of care but also enhance patient engagement and satisfaction through evidence-backed, data-informed clinical decision-making.

The IBD Living Guidelines Real-World Evidence Study embodies a critical nexus in the ongoing endeavor to bridge clinical research and everyday practice. Traditionally, clinical trials and guidelines have operated in somewhat insular environments, often failing to reflect the complexities and heterogeneity of community practice populations. The infusion of real-world evidence, powered by advanced AI methodologies, permits a dynamic feedback loop wherein guidelines can be continuously validated, refined, and contextualized against authentic patient experiences and outcomes.

Moreover, this initiative exemplifies the broader paradigm shift within medicine toward data-driven, precision approaches that leverage vast clinical datasets alongside machine intelligence. By moving beyond retrospective chart reviews and claims data, the utilization of comprehensive EHR-derived real-world data enables multidimensional analyses encompassing clinical nuance, therapeutic sequencing, and longitudinal patient follow-up, all at scale.

Ultimately, the collaborative framework established by AGA, Latica, Gastro Health, and Allied Digestive Health sets a new standard for how specialty societies and healthcare providers can harness digital innovation to transform chronic disease management. The insights generated through this study will not only inform future iterations of living guidelines for ulcerative colitis but will also serve as a blueprint for applying similar cutting-edge methodologies across other gastrointestinal disorders and medical specialties.

As the field of gastroenterology continues to evolve in the era of personalized medicine, initiatives such as this underscore the vital importance of integrating AI-powered real-world evidence to enhance clinical decision-making and improve patient-centered outcomes. By fostering ongoing, iterative dialogue between guideline development and real-world clinical practice, the IBD Living Guidelines Real-World Evidence Study represents a pivotal step toward truly adaptive, responsive, and effective gastrointestinal healthcare.

Subject of Research:
Article Title:
News Publication Date: August 26, 2025
Web References: https://www.gastro.org/, https://latica.ai/, http://gastrohealth.com/, http://allieddigestivehealth.com/
References:
Image Credits:

Keywords: Gastroenterology, Inflammatory Bowel Disease, Ulcerative Colitis, Living Guidelines, Real-World Evidence, Artificial Intelligence, Machine Learning, Natural Language Processing, Electronic Health Records, Clinical Decision Support, Community Health Data, Precision Medicine

Ulcerative colitis, characterized by persistent inflammation of the colonic mucosa, manifests clinically through severe abdominal discomfort, frequent diarrhea, rectal bleeding, and systemic manifestations such as weight loss and fatigue. Existing pharmacotherapies, including aminosalicylic acids, corticosteroids, and immunosuppressive agents, while standard, are often burdened with significant adverse effects and variable efficacy. Notably, anti-TNFα biological agents, though effective, suffer from limitations such as parenteral administration and high cost, sparking the urgent need for novel, orally available therapeutics with favorable safety profiles.

The investigative team approached this challenge by conducting comprehensive in vitro screenings of numerous cellular metabolites to identify candidates capable of modulating the pro-inflammatory TNFα/NF-κB signaling axis known to drive intestinal inflammation in UC. Pyruvate emerged as a standout molecule, exhibiting robust inhibition of TNFα-mediated NF-κB activation. Subsequent in vivo validation using dextran sodium sulfate (DSS)-induced colitis mouse models demonstrated that oral pyruvate administration markedly ameliorated colonic inflammation, preserved mucosal architecture, and improved clinical indices of disease severity.

Histopathological analyses underscored pyruvate’s capacity to maintain intestinal epithelial barrier integrity, a critical factor often compromised in UC pathogenesis. Examination of tight junction components revealed that pyruvate restored expression of proteins including claudin-2, ZO-1, and occludin, fortifying the mucosal barrier against disruptive inflammatory insults. Consequently, pyruvate’s mechanism of action extends beyond mere immunomodulation, encompassing preservation of epithelial homeostasis.

Delving deeper into molecular mechanisms, the researchers pinpointed cytosolic phospholipase A2 (cPLA2) as a novel and essential pyruvate target. Employing sophisticated assays such as drug affinity responsive target stability (DARTS) and cellular thermal shift assays (CETSA), they demonstrated that pyruvate directly binds to and stabilizes cPLA2, shielding it from proteolytic degradation. This biochemical interaction is pivotal given that cPLA2 catalyzes the release of arachidonic acid, a precursor for a suite of pro-inflammatory lipid mediators implicated in NF-κB pathway activation and immune cell recruitment.

Functionally, the binding of pyruvate to cPLA2 attenuates the downstream cascade of inflammatory signaling, culminating in substantial reductions in key cytokines like interleukin-1β (IL-1β) and interleukin-6 (IL-6) within both systemic circulation and colonic tissue. The dampening of these cytokines is crucial, as they orchestrate the amplification and perpetuation of mucosal inflammation characteristic of UC. Importantly, these anti-inflammatory effects were abrogated in cPLA2-deficient murine models, confirming the indispensable role of cPLA2 as the mediator of pyruvate’s therapeutic efficacy.

Comparative analyses illustrated that pyruvate’s efficacy in alleviating colitis paralleled that of 5-aminosalicylic acid (5-ASA), the mainstay UC drug. However, pyruvate confers distinct advantages as a small-molecule oral agent with fewer side effects and a unique mechanism targeting cPLA2 and inflammatory signaling. The potential to circumvent the challenges associated with biological therapies, such as immunogenicity and inconvenient administration routes, positions pyruvate as an attractive candidate for the next generation of UC treatments.

The researchers also speculated on the broader implications of their findings. Given the centrality of the TNFα/NF-κB axis not only in UC but also in a plethora of inflammatory and autoimmune diseases, pyruvate’s modulatory action on cPLA2 could translate into therapeutic benefits across a spectrum of TNFα-associated disorders. This opens avenues for exploring pyruvate-based interventions in rheumatoid arthritis, psoriasis, and even certain neuroinflammatory conditions where aberrant NF-κB signaling exacerbates pathology.

The study’s multi-tiered approach, integrating cellular assays, murine disease models, and molecular mechanistic evaluations, underscores the robust scientific foundation underpinning the therapeutic promise of pyruvate. Additionally, the elucidation of pyruvate’s effect on tight junction proteins aligns with emerging paradigms that emphasize restoration of epithelial barrier function as a critical therapeutic endpoint in inflammatory bowel diseases.

Moreover, the methodological rigor surrounding the identification of cPLA2 as the direct molecular target was facilitated by advanced biochemical techniques adept at capturing protein-ligand interactions in a cellular context. The stability shifts in cPLA2 upon pyruvate binding highlight a nuanced regulatory mechanism, wherein metabolic intermediates can directly influence enzyme activity and degradation, adding a new dimension to metabolic regulation of inflammation.

Given the chronic and relapsing nature of UC, therapies that combine efficacy with tolerability and patient convenience are urgently needed. Pyruvate’s oral availability, coupled with its dual action on immune signaling and barrier stabilization, could revolutionize the clinical management of UC. The researchers advocate for the advancement of pyruvate into clinical trials to verify its safety and effectiveness in human subjects, which could ultimately transform therapeutic strategies for millions worldwide burdened by inflammatory bowel diseases.

This pioneering work exemplifies the growing intersection of metabolism and immunology, highlighting how key metabolic intermediates like pyruvate, traditionally studied within energy production frameworks, possess far-reaching regulatory capabilities influencing inflammation. The findings challenge researchers and clinicians alike to reconsider metabolic compounds as viable therapeutic agents beyond their canonical biological roles.

In sum, this study delineates a compelling narrative wherein exogenous pyruvate emerges not merely as a metabolic substrate but as a potent anti-inflammatory agent targeting the vital enzyme cPLA2, thereby disrupting the deleterious TNFα/NF-κB signaling pathway. This dual action framework offers a fresh, scientifically grounded hope for developing safer, more effective, and orally administered therapies for ulcerative colitis and potentially other chronic inflammatory conditions.

Subject of Research: Ulcerative colitis treatment via modulation of inflammatory pathways through metabolic intermediates

Article Title: Exogenous pyruvate is therapeutic against colitis by targeting cytosolic phospholipase A2

References:
Sadaf Hasan, Nabil Ghani, Xiangli Zhao, Julia Good, Chuan-ju Liu, Exogenous pyruvate is therapeutic against colitis by targeting cytosolic phospholipase A2, Genes & Diseases, 2025, 101571.

Image Credits: Genes & Diseases

Keywords: ulcerative colitis, pyruvate, cytosolic phospholipase A2, TNFα, NF-κB signaling, inflammatory bowel disease, tight junction proteins, IL-1β, IL-6, arachidonic acid, DSS-induced colitis, oral therapy

Ulcerative colitis generally necessitates long-term management involving various antioxidant and anti-inflammatory pharmaceutical agents. However, these medications often carry the drawback of unwanted side effects that can complicate patient compliance and quality of life. In this light, natural products with antioxidative and anti-inflammatory capabilities have garnered increasing attention for their potential to serve as safer adjuncts or alternatives to conventional therapies.

Researchers from the University of Jendouba in Tunisia undertook a controlled study wherein rats were administered preemptive doses of an extract derived from Arbutus unedo. Subsequent to this pretreatment, the animals were exposed to acetic acid, a chemical agent known to induce experimental ulcerative colitis that mimics many pathological features observed in humans. This experimental design allowed the team to precisely evaluate the protective effects of the plant extract prior to the onset of colonic injury.

Histological analyses revealed that rats pretreated with Arbutus unedo extract exhibited remarkable preservation of colon tissue architecture, with a significant reduction in mucosal damage compared to untreated controls. The colonic lining remained more intact, and there was a conspicuous decrease in the formation of lesions, which are hallmark indicators of colitis severity. These morphological improvements strongly indicate that the plant extract confers a protective barrier against chemically induced inflammatory insults.

Biochemically, the extract’s influence extended to modulating molecular markers associated with oxidative stress—a major driver of inflammatory tissue injury. Specifically, the pretreatment substantially downregulated the expression of proteins and enzymes that facilitate the production of reactive oxygen species (ROS), thereby mitigating the oxidative burden on colon cells. This action interrupts the cycle of tissue damage perpetuated by unchecked free radical activity during ulcerative colitis.

Further examination uncovered the plant extract’s robust anti-inflammatory properties at the molecular level. The expression of pro-inflammatory cytokines and signaling molecules, which typically exacerbate mucosal inflammation and recruit damaging immune cells, was significantly diminished following pretreatment. This dual effect of reducing both oxidative stress and inflammation suggests a comprehensive mechanism through which Arbutus unedo exerts its therapeutic benefits.

Notably, the study underscores the potential of Arbutus unedo as not only a treatment modality but also a preventative agent. By administering the extract prior to chemical injury, researchers demonstrated that it may enhance the colon’s resilience and ability to withstand inflammatory triggers. This positions the plant as a promising candidate for developing prophylactic interventions aimed at reducing the incidence or severity of ulcerative colitis flare-ups.

Critical to understanding these outcomes is the phytochemical composition of Arbutus unedo. The strawberry tree is rich in polyphenols, flavonoids, and tannins—all bioactive compounds with documented antioxidant capacity. These molecules can scavenge harmful free radicals, chelate pro-oxidant metals, and modulate intracellular signaling pathways involved in inflammation. The synergy among these constituents likely underpins the protective effects observed in the study.

While the findings in rat models are compelling, translation to human clinical practice necessitates cautious progression through rigorous trials. Dose optimization, bioavailability, safety profiling, and efficacy evaluations in human subjects remain essential subsequent steps. However, the compelling evidence provided by this research lays a critical foundation for the future inclusion of Arbutus unedo in integrated therapeutic strategies for ulcerative colitis.

Moreover, this work contributes to a broader scientific dialogue emphasizing the significance of plant-based natural products in managing complex chronic diseases. By pairing traditional ethnobotanical knowledge with contemporary biochemical methodologies, researchers can continue to uncover novel bioactives that may revolutionize treatment paradigms.

The study also opens avenues for exploration into related gastrointestinal pathologies where oxidative stress and inflammation play pivotal roles, such as Crohn’s disease and colorectal cancer. Investigating the versatility of Arbutus unedo extract across these conditions could reveal broader applications and foster the development of multi-targeted botanical therapeutics.

In summation, the protective preconditioning afforded by Arbutus unedo extract articulates a promising intersection between natural product research and translational medicine. This innovative approach highlights the value of exploring region-specific flora for their medicinal properties, leveraging biodiversity to address unmet clinical needs in inflammatory bowel diseases.

Soumaya Wahabi, PhD, the study’s corresponding author, emphasizes that these findings warrant more extensive research focusing on both preventive and therapeutic roles of Arbutus unedo in gastrointestinal disorders. Expanding our understanding of this plant’s impact could ultimately translate into novel, effective, and safer treatment options for patients suffering from ulcerative colitis worldwide.

Subject of Research: Protective effects of Arbutus unedo extract on ulcerative colitis in rat models.

Article Title: Protective Effects of Arbutus unedo Extract on Acetic Acid-Induced Colitis in Rats: Histological, Biochemical, and Antioxidant Assessments

News Publication Date: 21-May-2025

Web References:
Journal of the Science of Food and Agriculture
DOI: 10.1002/jsfa.14317

Keywords: Ulcerative colitis, Inflammatory bowel diseases, Oxidative stress, Rat models, Animal models, Trees